HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Quality care does not require ‘throwing money down the drain’
-
- Imbruvica approval marks ‘new era’ for CLL treatment
- Amifostine improved cisplatin-induced hearing loss in average-risk medulloblastoma
- Post-induction PET indicated risk for progression in follicular lymphoma
- Recombinant Factor VIII Fc fusion protein effective in severe hemophilia A
- VTE after major cancer surgery varied by race, insurance coverage
- USPSTF supports BRCA-related cancer screening in women with family history
- FOLFOXIRI plus bevacizumab may benefit patients with BRAF-mutant metastatic colorectal cancer
- Real, sham acupuncture improved patient-reported outcomes in breast cancer
-
- Axillary lymph node dissection failed to improve outcomes in T1N0 breast cancer
- BRAF mutation in localized melanomas meant poor prognosis
- Erlotinib provided benefit in EGFR-mutant NSCLC
- Primary surgery superior to induction selection chemotherapy in advanced oral cavity carcinoma
- Stages II, III scalp melanoma patients experienced poor overall survival
- Stringent complete response associated with improved survival after ASCT for multiple myeloma
- Surgery, surveillance may obviate chemotherapy in 50% of stage I pediatric malignant ovarian germ cell tumors
- Vismodegib safety, efficacy confirmed in advanced BCC patients
-
- Peripheral blood leukocyte telomere length linked to glioma risk
- Two microRNA diagnostic panels may detect pancreatic cancer
- Center appoints interim director
- Hematologists join cancer care alliance
- Yale appoints research program leader for head and neck cancers
- Enzalutamide extended OS, PFS in chemotherapy-naive prostate cancer
- Idelalisib plus rituximab extended survival in previously treated CLL
- Radiotherapy plus hormone therapy halved prostate cancer mortality
-
- Angiotensin system inhibitors extended PFS, OS in renal cell carcinoma
- Multimodal approach appears promising for treatment of cancer cachexia